.png){kind=icon}
.png){kind=icon}
Return
QIAreach® QuantiFERON-TB diagnostic performance to detect tuberculosis infection among people living with HIV in Brazil: a prospective study
.png){kind=icon}
OA
AI
R
A
A
M
B
E
B
V
S
B
L
J
M
DOI：10.1016/j.jiph.2026.103281.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Identifying individuals with tuberculosis infection (TBI) at increased risk of progressing to active TB remains challenging. The World Health Organization recommends both the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA), including QuantiFERON-TB Gold Plus (QFT®-Plus), for the detection of TBI. QIAreach®, a novel IGRA assay designed for resource-limited settings, has shown strong concordance with QFT®-Plus. However, data on immunosuppressed individuals are limited. To address this gap, we assessed the diagnostic performance of QIAreach® compared with QFT®-Plus in a high TB/HIV-burden setting.
Keywords:
ART
antiretroviral therapy
CI
confidence interval
FMT-HVD
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
FN
false negatives
FP
false positives
HIV
human immunodeficiency virus
IFN-γ
interferon-gamma
IGRA
interferon-gamma release assay
Mtb
Mycobacterium tuberculosis
NPV
negative predictive value
PLHIV
people living with HIV
QFT-Plus
QuantiFERON-TB Gold Plus
QIAreach
QuantiFERON-TB QIAreach
TB
tuberculosis
TBI
tuberculosis infection
TN
true negatives
TP
true positives
TPT
tuberculosis preventive treatment
TST
tuberculin skin test
WHO
World Health Organization
QIAreach® QuantiFERON-TB
diagnostic performance
HIV
TBI
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4
Papers:
570
Citations:
7.0K
Organization
Cited Papers